A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Tagraxofusp (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stemline Therapeutics
- 01 Oct 2022 Results of an integrated analysis assessing aggregated safety data for Tagraxofusp monotherapy from three clinical trials: Study 0114, Study 0214 and Study 0314 published in the Clinical Lymphoma, Myeloma & Leukemia
- 13 Jan 2022 Status changed from completed to discontinued.
- 14 Dec 2021 Results from three phase 1/2 studies (Study 0114 (NCT02113982), Study 0214 (NCT02270463), and Study 0314 (NCT02268253) presented at the 63rd American Society of Hematology Annual Meeting and Exposition